Save
Email
Print
ShareJan. 23, 2013 — In a demonstration of the power of green chemistry, scientists are reporting development of a new and more efficient process for making one of the most costly and widely used medications for severe mental illness. Described in a report in the journal ACS Sustainable Chemistry & Engineering, it produces larger amounts of the medication than the existing commercial process while reducing the use of solvents and other potentially toxic substances.
Vijayavitthal T. Mathad and colleagues point out that paliperidone, marketed under the brand name Invega, is one of a new generation of medicines for schizophrenia, a severe form of mental illness. Paliperidone has advantages over other medicines, but the current process for making it is expensive and inefficient, contributing to the drug's cost -- about $18 per tablet in the United States. The process also requires use and disposal of large amounts of solvents that require special handling.
They describe development of a new recipe for making paliperidone. It not only yields larger amounts of the medicine, but uses less solvent and involves an innovative and environmentally friendly method for purifying the medication and for the control and removal of critical impurities that result from the process and carryover from raw materials. The sustainability of the process lies in its capability to withstand the cost pressure when the drug becomes completely generic, the authors said. Reducing the raw material cost not only makes it sustainable but it should be environmentally and production-friendly.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by American Chemical Society.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Pavankumar V. Solanki, Sekhar Babu Uppelli, Bhushan S. Pandit, Vijayavitthal T. Mathad. An Improved and Efficient Process for the Production of Highly Pure Paliperidone, a Psychotropic Agent, via DBU CatalyzedN-Alkylation. ACS Sustainable Chemistry & Engineering, 2013; : 130109143517005 DOI: 10.1021/sc3000916
Note: If no author is given, the source is cited instead.
more 
